이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Accelerate Diagnostics 관리

관리 기준 확인 1/4

Accelerate Diagnostics' CEO는 Jack Phillips, Feb2020 에 임명되었습니다 의 임기는 4.33 년입니다. 총 연간 보상은 $ 3.00M, 19.8% 로 구성됩니다. 19.8% 급여 및 80.2% 보너스(회사 주식 및 옵션 포함). 는 $ 188.99K 가치에 해당하는 회사 주식의 0.69% 직접 소유합니다. 188.99K. 경영진과 이사회의 평균 재임 기간은 각각 1.4 년과 4.1 년입니다.

주요 정보

Jack Phillips

최고 경영자

US$3.0m

총 보상

CEO 급여 비율	19.8%
CEO 임기	4.3yrs
CEO 소유권	0.7%
경영진 평균 재임 기간	1.4yrs
이사회 평균 재임 기간	4.1yrs

최근 관리 업데이트

Recent updates

Market Participants Recognise Accelerate Diagnostics, Inc.'s (NASDAQ:AXDX) Revenues Pushing Shares 38% Higher

Apr 17

Accelerate Diagnostics spikes as Chief Technology Officer raises stake

Aug 30

Need To Know: Analysts Are Much More Bullish On Accelerate Diagnostics, Inc. (NASDAQ:AXDX)

Aug 20

Accelerate Diagnostics jumps 14% after beating Q2 estimates

Aug 15

Need To Know: The Consensus Just Cut Its Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Estimates For 2022

Mar 15

Accelerate Diagnostics And T2 Biosystems: Financial Woes Set To Continue In 2022

Jan 04

Accelerate Diagnostics: An Investment Assessment

Sep 07

Should You Take Comfort From Insider Transactions At Accelerate Diagnostics, Inc. (NASDAQ:AXDX)?

Feb 20

Accelerate Diagnostics foresees Q4 and FY2020 revenue below consensus

Jan 12

Reflecting on Accelerate Diagnostics' (NASDAQ:AXDX) Share Price Returns Over The Last Three Years

Dec 29

CEO 보상 분석

Jack Phillips 의 보수는 Accelerate Diagnostics 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-US$59m
Dec 31 2023	US$3m	US$595k	-US$62m
Sep 30 2023	n/a	n/a	-US$63m
Jun 30 2023	n/a	n/a	-US$80m
Mar 31 2023	n/a	n/a	-US$66m
Dec 31 2022	US$2m	US$595k	-US$62m
Sep 30 2022	n/a	n/a	-US$71m
Jun 30 2022	n/a	n/a	-US$64m
Mar 31 2022	n/a	n/a	-US$67m
Dec 31 2021	US$3m	US$595k	-US$78m
Sep 30 2021	n/a	n/a	-US$74m
Jun 30 2021	n/a	n/a	-US$84m
Mar 31 2021	n/a	n/a	-US$81m
Dec 31 2020	US$4m	US$555k	-US$78m
Sep 30 2020	n/a	n/a	-US$81m
Jun 30 2020	n/a	n/a	-US$82m
Mar 31 2020	n/a	n/a	-US$84m
Dec 31 2019	US$12m	US$162k	-US$84m

보상 대 시장: Jack 의 총 보상 ($USD 3.00M )은 US 시장( $USD 683.56K ).

보상과 수익: 회사가 수익성이 없는 동안 Jack 의 보상이 증가했습니다.

CEO

Jack Phillips (58 yo)

4.3yrs

테뉴어

US$3,004,105

보상

Mr. Jack Phillips has been Chief Executive Officer, President and Director of Accelerate Diagnostics, Inc. since February 1, 2020. Mr. Phillips served as Chief Operating Officer of Accelerate Diagnostics,...

리더십 팀

이름	위치	테뉴어	보상	소유권
Jack Phillips	CEO, President & Director	4.3yrs	US$3.00m	0.69% $ 187.4k
David Patience	Chief Financial Officer	1.2yrs	US$1.16m	0.22% $ 58.9k
Lawrence Mertz	Chief Technology Officer	2yrs	US$952.16k	0.35% $ 94.3k
Maya Gowri	Senior VP & Head of Operations	1.4yrs	데이터 없음	데이터 없음
Laura Pierson	Investor Relations Officer	no data	데이터 없음	데이터 없음
John Meduri	Chief Strategy Officer	8.3yrs	데이터 없음	데이터 없음
Chris Thode	Senior Vice President of US Commercial	1.4yrs	데이터 없음	데이터 없음
Rita Boukamel	Senior VP & Head of EMEA	1.3yrs	데이터 없음	데이터 없음

1.4yrs

평균 재임 기간

58yo

평균 연령

경험이 풍부한 관리: AXDX 의 관리팀은 경험 (평균 재직 기간 1.4 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Jack Phillips	CEO, President & Director	4.3yrs	US$3.00m	0.69% $ 187.4k
John Patience	Independent Director	12yrs	US$231.32k	2.84% $ 771.9k
Jack Schuler	Independent Director	12yrs	US$231.32k	36.13% $ 9.8m
Hany Massarany	Independent Chairman of the Board	4.1yrs	US$231.32k	0.15% $ 40.4k
Louise Francesconi	Independent Director	4.5yrs	US$231.32k	0.12% $ 33.1k
Marran J. Ogilvie	Independent Director	1.1yrs	US$233.68k	데이터 없음
Marin Kollef	Scientific Advisory Board Member	no data	데이터 없음	데이터 없음
Connie Price	Scientific Advisory Board Member	no data	데이터 없음	데이터 없음
Mark Black	Independent Director	1.1yrs	US$233.68k	데이터 없음
Richard Wunderink	Scientific Advisory Board Member	no data	데이터 없음	데이터 없음
Wayne Burris	Independent Director	2.3yrs	US$231.32k	0.0071% $ 1.9k
Jenny Regan	Independent Director	1.1yrs	US$233.68k	0.053% $ 14.5k

4.1yrs

평균 재임 기간

65yo

평균 연령

경험이 풍부한 이사회: AXDX 의 이사회는 경험(평균 재직 기간 4.1 년)으로 간주됩니다.

Accelerate Diagnostics 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Accelerate Diagnostics, Inc., Annual General Meeting, May 07, 2024

CEO, President & Director exercised options and sold US$73k worth of stock

Insufficient new directors

Accelerate Diagnostics, Inc. Announces Resignation of Ron Price as Chief Commercial Officer

Insider recently bought US$80k worth of stock

CEO, President & Director exercised options and sold US$26k worth of stock

Recent updates

Accelerate Diagnostics, Inc. to Report Q1, 2024 Results on May 08, 2024

Accelerate Diagnostics, Inc. Receives Written Notice from the Listing Qualifications Staff of Nasdaq

Accelerate Diagnostics, Inc., Annual General Meeting, May 07, 2024

Accelerate Diagnostics, Inc. Receives Written Notice from the Listing Qualifications Staff of the Nasdaq Stock Market, LLC

Accelerate Diagnostics, Inc. announced that it expects to receive $4.749996 million in funding from Jack W. Schuler Living Trust

Accelerate Diagnostics, Inc. has completed a Composite Units Offering.

Accelerate Diagnostics Announces 1-For-10 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement of $1.00 Per Share Required to Maintain Continued Listing on the Nasdaq Capital Market

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 15%

Market Participants Recognise Accelerate Diagnostics, Inc.'s (NASDAQ:AXDX) Revenues Pushing Shares 38% Higher

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

CEO, President & Director exercised options and sold US$73k worth of stock

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Insufficient new directors

Accelerate Diagnostics Receives A Deficiency Letter from Nasdaq Regarding Minimum Bid Price Requirement

Accelerate Diagnostics Submits 510(K) Application to FDA for Gram-Negative Menu Expansion and Breakpoint Updates for the Accelerate Phenotest(R) BC Kit

Accelerate Diagnostics, Inc. Announces Resignation of Ron Price as Chief Commercial Officer

Consensus forecasts updated

Price target decreased to US$2.00

Accelerate Diagnostics, Inc. Provides Earnings Guidance for the Year 2022

Insider recently bought US$80k worth of stock

Accelerate Diagnostics spikes as Chief Technology Officer raises stake

Consensus revenue estimates increase by 10%

Need To Know: Analysts Are Much More Bullish On Accelerate Diagnostics, Inc. (NASDAQ:AXDX)

Accelerate Diagnostics, Inc. has completed a Follow-on Equity Offering in the amount of $35 million.

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Accelerate Diagnostics jumps 14% after beating Q2 estimates

CEO, President & Director exercised options and sold US$26k worth of stock

Consensus forecasts updated

Accelerate Diagnostics Announces Commercialization of its Accelerate Arc System Having Completed IVD Registration with FDA

First quarter 2022 earnings: EPS exceeds analyst expectations

CEO, President & Director exercised options and sold US$82k worth of stock

Price target decreased to US$5.00

Accelerate Diagnostics, Inc., Annual General Meeting, May 12, 2022

Accelerate Diagnostics, Inc. Announces Launch of Accelerate Arc™ Module and BC Kit

Need To Know: The Consensus Just Cut Its Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Estimates For 2022

Consensus revenue estimates fall by 14%

Full year 2021 earnings: EPS exceeds analyst expectations

Accelerate Diagnostics, Inc. Elects Wayne C. Burris as Member of the Board

Insider recently bought US$66k worth of stock

Independent Director recently bought US$524k worth of stock

Independent Director recently bought US$196k worth of stock

Accelerate Diagnostics, Inc. Provides Revenue Guidance for Fourth Quarter and Full Year 2021

Independent Director recently bought US$277k worth of stock

Accelerate Diagnostics And T2 Biosystems: Financial Woes Set To Continue In 2022

Independent Director recently bought US$369k worth of stock

Independent Director recently bought US$248k worth of stock

Independent Director recently bought US$606k worth of stock

Accelerate Diagnostics, Inc. Announces New Accelerate Pheno System Multi-Center Study Published in Clinical Infectious Diseases

Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.33 loss in 3Q 2020)

Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.33 loss in 3Q 2020)

Accelerate Diagnostics, Inc. announced that it has received $1.55 million in funding

Independent Director recently bought US$150k worth of stock

Price target decreased to US$11.00

Accelerate Diagnostics: An Investment Assessment

Second quarter 2021 earnings released: US$0.35 loss per share (vs US$0.35 loss in 2Q 2020)

Consensus forecasts updated

Accelerate Diagnostics, Inc. to present New Accelerate Pheno® Landmark Study Validates Important Clinical Benefits at ECCMID 2021

CEO, President & Director exercised options and sold US$186k worth of stock

Key Executive exercised options and sold US$56k worth of stock

Price target decreased to US$11.00

First quarter 2021 earnings released: US$0.41 loss per share (vs US$0.39 loss in 1Q 2020)

Accelerate Diagnostics, Inc. Announces Roland D. Diggelmann Decision Not to Stand for Re-Election to Its Board

Analysts lower revenue estimates to US$16.5m

Earnings beat expectations, revenue disappoints

Full year 2020 earnings released: US$1.40 loss per share (vs US$1.55 loss in FY 2019)

Should You Take Comfort From Insider Transactions At Accelerate Diagnostics, Inc. (NASDAQ:AXDX)?

Key Executive exercised options and sold US$701k worth of stock

New 90-day high: US$12.96